Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid

被引:20
作者
Rajaram, Subashini [1 ]
Vemuri, Venkata Deepthi [1 ]
Natham, Rajendran [1 ]
机构
[1] Swamy Vivekanandha Coll Pharm, Dept Pharmaceut, Namakkal 637205, Tamil Nadu, India
关键词
Ascorbic acid; Bioavailability; Pharmacokinetics; Rifampicin; Tuberculosis; DRUG-DELIVERY SYSTEM; GLOBAL EPIDEMIOLOGY; BIOAVAILABILITY; MICROSPHERES; RELEASE;
D O I
10.1016/j.jpba.2014.07.027
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Bioavailability of rifampicin (RIF) from fixed dose combination (FDC) products remains problematic for effective control of tuberculosis (TB) owing to its degradation in the presence of isoniazid (INH) in the stomach acid environment. Ascorbic acid (ASC) is being added to the dissolution medium as well as the plasma sample as anti-oxidant to prevent degradation of RIF and also daily intake of ascorbic acid is recommended to control TB infection. However the role of ASC on the interaction between dissolution stability and in vivo bioavailability of RIF in the presence of INH has not been explored and therefore examined in the present study. RIF and its degradation product 3-FRSV were measured by dual wavelength spectroscopy. ASC significantly reduced RIF degradation or formation of 3-FRSV in the presence of INH (p < 0.001) in the dissolution medium (pH 1.2) and showed increase in C-max, AUC(0-24), AUC(0-infinity) and t(1/2) of RIF (p < 0.001) as compared to that without ASC in rabbits. The study demonstrates that co-administration of ASC with RIF-INH combination can protect RIF from degradation in the acid environment and improve its bioavailability with effective control of TB. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:103 / 108
页数:6
相关论文
共 22 条
[1]   Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses [J].
Ahmad, Zahoor ;
Pandey, Rajesh ;
Sharma, Sadhna ;
Khuller, Gopal K. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 27 (05) :409-416
[2]  
Awodele O., 2010, TANZANIA J HLTH RES, V12, P1
[3]   Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22
[4]   Global epidemiology of tuberculosis [J].
Dye, C .
LANCET, 2006, 367 (9514) :938-940
[5]   Controlled release of ionic compounds from poly (L-lactide) microspheres produced by precipitation with a compressed antisolvent [J].
Falk, R ;
Randolph, TW ;
Meyer, JD ;
Kelly, RM ;
Manning, MC .
JOURNAL OF CONTROLLED RELEASE, 1997, 44 (01) :77-85
[6]  
Gaurav K.S., 2010, INT J PHARMACEUT, V385, P43
[7]   MAINTENANCE OF THERAPEUTICALLY ACTIVE LEVELS OF ISONIAZID FOR PROLONGED PERIODS IN RABBITS AFTER A SINGLE IMPLANT OF BIODEGRADABLE POLYMER [J].
KAILASAM, S ;
DANELUZZI, D ;
GANGADHARAM, PRJ .
TUBERCLE AND LUNG DISEASE, 1994, 75 (05) :361-365
[8]  
Lee Guellec C., 1997, THER DRUG MONIT, V19, P669, DOI DOI 10.1097/00007691-199712000-00011
[9]   Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance [J].
Levine, M ;
ConryCantilena, C ;
Wang, YH ;
Welch, RW ;
Washko, PW ;
Dhariwal, KR ;
Park, JB ;
Lazarev, A ;
Graumlich, JF ;
King, J ;
Cantilena, LR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (08) :3704-3709
[10]   Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin [J].
Mohan, B ;
Sharda, N ;
Singh, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 31 (03) :607-612